A Florida doctor has opened a new chapter in bladder cancer research with the development of a new drug that has the potential to dramatically reduce bladder cancer patients’ risk of death.

Dr. Patrick O’Connor said that in his 30 years of experience treating bladder cancer, he has never seen such rapid progress with his drug.

The drug he developed is called Gomatidib, and it was recently named by Forbes as one of the most promising drugs on the market.

Dr O’Connell said Gomidib’s most important property is its ability to treat the cancer cells directly.

The drugs can kill the cancer, but the drugs also prevent the cancer from regrowing.

Dr O’Donnell said Gomaidib can kill a tumor that’s been in the bladder for two to three weeks, but that the cancer can be caught up in other organs and be too hard to treat.

“The cancer cells will still be there, but you can’t treat them,” he said.

Dr Dwayne Miller, who is also a professor at the University of Florida School of Medicine, said that the drug’s ability to slow the growth of the cancer makes it a much more viable therapy for bladder cancer.

“We know that bladder cancer cells do not regenerate,” Dr Miller said.

“The best thing we can do is get them to regrow as fast as possible, but we can’t do it by simply killing them off.”

Dr Miller said Gomasidib also has some advantages over other drugs.

The treatment does not require a hospital stay, and the drug can be given to people on a “dose-by-dose” basis.

The doctors are also hoping to create a new treatment called Gomaoid, which involves injecting Gomidsib into the patient.

“This is a way of delivering a lot of doses of the drug, which means that you could give it in a short amount of time, and then go back to your usual dose,” Dr Ollins said.

“You would have to take a second dose of Gomit to get the same effect.

That is a huge advantage.”

Dr Ollin said the drug would likely be available within a year, and that it could be used by people who have not yet reached the age of 50.

The treatment was developed in collaboration with a Brazilian company called Medecins Sans Frontieres.

Dr Miller described it as a “first-in-class” drug.

“It’s a really exciting, innovative drug, and I think that the future is bright for this treatment,” Dr Dwayne said.